Recent therapeutic trends and promising targets in triple negative breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Triple negative breast cancer (TNBC) constitutes 15-20% of all breast cancers.
• TNBC is characterized by aggressive proliferation, metastasis, and poor prognosis.
• Current treatments rely on conventional chemotherapy and radiation, with no FDA-approved targeted therapies.

Purpose of the Study:

• To review the complex tumorigenic processes in TNBC.
• To discuss critical findings and therapeutic trends in TNBC.
• To highlight promising therapeutic approaches and ongoing clinical trials.

Main Methods:

• Review of massive cohort studies and clinical trials.
• In-depth analysis of molecular alterations in TNBC.
• Evaluation of preclinical and experimental compounds.

Main Results:

• Diverse molecular alterations identified in TNBC, with ongoing debate on their role in cancer progression.
• Identification of promising therapeutic targets and experimental compounds.
• Overview of current clinical trials for TNBC treatment.

Conclusions:

• TNBC presents significant therapeutic challenges due to its aggressive nature and lack of targeted treatments.
• Ongoing research focuses on understanding molecular complexities to develop novel therapeutic strategies.
• Promising experimental compounds and clinical trials offer hope for improved TNBC management.